Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these

Abstract

The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.

1 - 16 . (canceled) 
     
     
         17 . A process for preparing a taurine derivative compound, comprising reacting taurine with a non-steroidal anti inflammatory (NSAI) compound in the presence of a catalyst in an organic media, wherein the taurine derivative compound is a compound of Formula (I) 
       
         
           
           
               
               
           
         
         and its salts, solvates, hydrates, enantiomers, diasteroisomers and polymorphs: 
         in which R is selected from the group consisting of: 
         2-[2-(2,6-dichlorophenylamino)phenyl]acetic acid, 
         2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid, 
         2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid, 
         2-[(2,3-dimethylphenyl)amino]benzoic acid, 
         [2-(2,4-dichlorophenoxy)phenyl]acetic acid, 
         2-[(3-chloro-2-methylphenyl)amino]benzoic acid, 
         2-[(1,2-diphenyl-hydrazine) carbonyl]hexanoic acid, 
         4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, 
         (1,3,4-triphenyl-1H-pyrazol-5-yl)acetic acid, 
         [3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid, 
         [(1-benzyl-1H-indazole-3-yl)oxy]acetic acid, 
         [4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid, 
         [2-(4-chlorophenyl)-1,3-thyazol-4-yl]acetic acid, 
         3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid, 
         [1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrol-3-yl]acetic acid, 
         2-amino-6-benzyl-4,5,6,7-tetrahydrothyen[2,3-c]pyridine-3-carboxylic acid, 
         2-(2-hydroxybenzoylic)acid, 
         [2-(aminocarbonyl)phenoxy]acetic acid, 
         2,5-dihydroxybenzoic acid, 
         2-(acetyloxy)benzoic acid, 
         2-(sulphooxy)benzoic acid, 
         2-[(2-hydroxybenzoyl)oxy]benzoic acid, 
         2-[(2-phenylethyl)amino]benzoic acid, 
         5-[(2-phenyl-4,5-dihydro-3H-benzo[e]-1H-indole-2-(2-hydroxybenzoic acid), 
         2′,4′-difluoro-4-hydroxy-1,1′-diphenyl-3-carboxilic acid, 
         2-(4-isobutylphenyl) butanoic acid, 
         2-(4-isobutylphenyl) propanoic acid, 
         2-[4-(thyen-2-yl-carbonyl)phenyl]propanoic acid, 
         2-(3-phenoxyphenyl) propanoic acid, 
         chloro(3-chloro-4-cyclo-hexylphenyl)acetic acid, 
         4-(3-chloro-4-cyclo-hexyl phenyl)-4-oxobutanoic acid, 
         6-chloro-5-cyclo-hexylindan-1-carboxilic acid, 
         2-{4-[(2-methylprop-2-enyl)amino]phenyl}propanoic acid, 
         2-(5-benzoylthyen-2-yl) propanoic acid, 
         5-benzoyl-2,3-dihydro-1H-pyrolizine-1-carboxilic acid, 
         2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid, 
         2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid, 
         2-(3-benzoylphenyl) propanoic acid, 
         2-(4-imidazo[1,2-a]pyridin-2-yl phenyl) propanoic acid, 
         [1-methyl-5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetic acid, 
         [5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrol-2-yl]acetic acid, 
         2-[3-chloro-4-(2,5-dihydro-1H-pyrol-1-yl)phenyl]propanoic acid, 
         (11-oxo-6,11-dihydroxibenzo[b,e]oxepin-2-yl)acetic acid, 
         2-(2-fluoro-1,1′-diphenyl-4-yl) propanoic acid, 
         [4-(allyoxy)-3-chlorophenyl]acetic acid, 
         2-[4-(1-oxo-1,3-dihydro-2H-isoindoie-2-yl)phenyl]propanoic acid, 
         2-[4-(2,5-dihydrothyen-2-yl carbonyl)phenyl]propanoic acid, 
         2-(5H-chromeno[2,3-b]pyridin-7-yl) propanoic acid, 
         4-(1,1′-diphenyl-4-yl)-4-oxobutanoic acid, 
         1,1′-diphenyl-4-yl acetic acid, 
         2-(6-methoxy-2-naphtyl) propanoic acid, 
         [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetic acid, 
         {5-methoxy-2-methyl-1-[(2E)-3-phenylprop-2-enoy]-1H-indole-3-yl}acetic acid, 
         ({[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetyl}oxy)acetic acid, 
         (1,8-diethyl-1,3,4,9-tetrahydrofurane[3,4-b]indole-1-yl)acetic acid, 
         {(1E)-5-fluoro-2-methyl-1-[4-(methylsulphinyl)benzylidene]-1H-inden-3-yl}acetic acid, and 2-(6-chloro-9H-carbazol-2-yl) propanoic acid. 
       
     
     
         18 . The process according to  claim 17 , wherein the process is a process of latentiation. 
     
     
         19 . The process according to  claim 17 , wherein the NSAI compound is selected from the group consisting of: salycilates, pyrazolons and its analogs, derived indoleacetics, derived arilacetics, derived arylpropionics, oxycams, and phenamates. 
     
     
         20 . The process according to  claim 19 , wherein the NSAI compound is selected from the group consisting of:
 2-[2-(2,6-dichlorophenylamino)phenyl]acetic acid,   2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid,   2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid,   2-[(2,3-dimethylphenyl)amino]benzoic acid,   [2-(2,4-dichlorophenoxy)phenyl]acetic acid,   2-[(3-chloro-2-methylphenyl)amino]benzoic acid,   2-[(1,2-diphenyl-hydrazine) carbonyl]hexanoic acid,   4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid,   (1,3,4-triphenyl-1H-pyrazol-5-yl)acetic acid,   [3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid,   [(1-benzyl-1H-indazole-3-yl)oxy]acetic acid,   [4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid,   [2-(4-chlorophenyl)-1,3-thyazol-4-yl]acetic acid,   3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid,   [1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrol-3-yl]acetic acid,   2-amino-6-benzyl-4,5,6,7-tetrahydrothyen[2,3-c]pyridine-3-carboxylic acid,   2-(2-hydroxybenzoic)acid,   [2-(aminocarbonyl)phenoxy]acetic acid,   2,5-dihydroxybenzoic acid,   2-(acetyloxy)benzoic acid,   2-(sulphooxy)benzoic acid,   2-[(2-hydroxybenzoyl)oxy]benzoic acid,   2-[(2-phenylethyl)amino]benzoic acid,   5-[(2-phenyl-4,5-dihydro-3H-benzo[e]-1H-indole-2-(2-hydroxybenzoic acid),   2′,4′-difluoro-4-hydroxy-1,1′-diphenyl-3-carboxilic acid,   2-(4-isobutylphenyl) butanoic acid,   2-(4-isobutylphenyl) propanoic acid,   2-[4-(thyen-2-yl-carbonyl)phenyl]propanoic acid,   2-(3-phenoxyphenyl) propanoic acid,   chloro(3-chloro-4-cyclo-hexylphenyl)acetic acid,   4-(3-chloro-4-cyclo-hexyl phenyl)-4-oxobutanoic acid,   6-chloro-5-cyclo-hexylindan-1-carboxilic acid,   2-{4-[(2-methylprop-2-enyl)amino]phenyl}propanoic acid,   2-(5-benzoylthyen-2-yl) propanoic acid,   5-benzoyl-2,3-dihydro-1H-pyrolizine-1-carboxilic acid,   2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid,   2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid,   2-(3-benzoylphenyl) propanoic acid,   2-(4-imidazo[1,2-a]pyridin-2-yl phenyl) propanoic acid,   [1-methyl-5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetic acid,   [5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrol-2-yl]acetic acid,   2-[3-chloro-4-(2,5-dihydro-1H-pyrol-1-yl)phenyl]propanoic acid,   (11-oxo-6,11-dihydroxibenzo[b,e]oxepin-2-yl)acetic acid,   2-(2-fluoro-1,1′-diphenyl-4-yl) propanoic acid,   [4-(allyloxy)-3-chlorophenyl]acetic acid,   2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl)phenyl]propanoic acid,   2-[4-(2,5-dihydrothyen-2-yl carbonyl)phenyl]propanoic acid,   2-(5H-chromeno[2,3-b]pyridin-7-yl) propanoic acid,   4-(1,1′-diphenyl-4-yl)-4-oxobutanoic acid,   1,1′-diphenyl-4-yl acetic acid,   2-(6-methoxy-2-naphtyl) propanoic acid,   [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetic acid,   {5-methoxy-2-methyl-1-[(2E)-3-phenylprop-2-enoyl]-1H-indole-3-yl}acetic acid,   ({[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetyl}oxy)acetic acid,   (1,8-diethyl-1,3,4,9-tetrahydrofurane[3,4-b]indole-1-yl)acetic acid,   {(1E)-5-fluoro-2-methyl-1-[4-(methylsulphinyl)benzylidene]-1H-inden-3-yl}acetic acid, and 2-(6-chloro-9H-carbazol-2-yl) propanoic acid.   
     
     
         21 . The process according to  claim 17 , wherein the NSAI compound is selected from the group consisting of: 2-(4-isobutylphenyl) butanoic acid, 2-(6-methoxy-2-naphtyl) propanoic acid and [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetic acid. 
     
     
         22 . The process according to  claim 17 , wherein the catalyst is selected from group consisting of: diethylcyanophosphonate, 1-hydroxybenzotriazole, carbodiimides, triethyamine, imidazole, pyrazole, 1,2,4-triazole, 4-dimethyl aminopyridine, and pyridine. 
     
     
         23 . The process according to  claim 17 , wherein the catalyst is diethylcyanophosphonate. 
     
     
         24 . The process according to  claim 17 , wherein the organic media is an organic solvent selected from the group consisting of acetone, tetrahydrofuran and dimethylformamide. 
     
     
         25 . The process according to  claim 17 , wherein the process is performed at room temperature and pH is highly alkaline. 
     
     
         26 . A pharmaceutical composition comprising:
 (a) a pharmacologically-effective quantity of at least one taurine derivative compound;   (b) optionally a pharmacologically-effective quantity of at least one active principle for the treatment of a medical condition involving an inflammatory disturbance; and   (c) a pharmaceutically acceptable vehicle,
 wherein the taurine derivative compound is a compound of Formula (I) 
   
       
         
           
           
               
               
           
         
         and its salts, solvates, hydrates, enantiomers, diasteroisomers and polymorphs: 
         in which R is selected from the group consisting of: 
         2-[2-(2,6-dichlorophenylamino)phenyl]acetic acid, 
         2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid, 
         2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid, 
         2-[(2,3-dimethylphenyl)amino]benzoic acid, 
         [2-(2,4-dichlorophenoxy)phenyl]acetic acid, 
         2-[(3-chloro-2-methylphenyl)amino]benzoic acid, 
         2-[(1,2-diphenyl-hydrazine) carbonyl]hexanoic acid, 
         4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, 
         (1,3,4-triphenyl-1H-pyrazol-5-yl)acetic acid, 
         [3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid, 
         [(1-benzyl-1H-indazole-3-yl)oxy]acetic acid, 
         [4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid, 
         [2-(4-chlorophenyl)-1,3-thyazol-4-yl]acetic acid, 
         3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid, 
         [1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrol-3-yl]acetic acid, 
         2-amino-6-benzyl-4,5,6,7-tetrahydrothyen[2,3-c]pyridine-3-carboxylic acid, 
         2-(2-hydroxybenzoylic)acid, 
         [2-(aminocarbonyl)phenoxy]acetic acid, 
         2,5-dihydroxybenzoic acid, 
         2-(acetyloxy)benzoic acid, 
         2-(sulphooxy)benzoic acid, 
         2-[(2-hydroxybenzoyl)oxy]benzoic acid, 
         2-[(2-phenylethyl)amino]benzoic acid, 
         5-[(2-phenyl-4,5-dihydro-3H-benzo[e]-1H-indole-2-(2-hydroxybenzoic acid), 
         2′,4′-difluoro-4-hydroxy-1,1′-diphenyl-3-carboxilic acid, 
         2-(4-isobutylphenyl) butanoic acid, 
         2-(4-isobutylphenyl) propanoic acid, 
         2-[4-(thyen-2-yl-carbonyl)phenyl]propanoic acid, 
         2-(3-phenoxyphenyl) propanoic acid, 
         chloro(3-chloro-4-cyclo-hexylphenyl)acetic acid, 
         4-(3-chloro-4-cyclo-hexyl phenyl)-4-oxobutanoic acid, 
         6-chloro-5-cyclo-hexylindan-1-carboxilic acid, 
         2-{4-[(2-methylprop-2-enyl)amino]phenyl}propanoic acid, 
         2-(5-benzoylthyen-2-yl) propanoic acid, 
         5-benzoyl-2,3-dihydro-1H-pyrolizine-1-carboxilic acid, 
         2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid, 
         2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid, 
         2-(3-benzoylphenyl) propanoic acid, 
         2-(4-imidazo[1,2-a]pyridin-2-yl phenyl) propanoic acid, 
         [1-methyl-5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetic acid, 
         [5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrol-2-yl]acetic acid, 
         2-[3-chloro-4-(2,5-dihydro-1H-pyrol-1-yl)phenyl]propanoic acid, 
         (11-oxo-6,11-dihydroxibenzo[b,e]oxepin-2-yl)acetic acid, 
         2-(2-fluoro-1,1′-diphenyl-4-yl) propanoic acid, 
         [4-(allyloxy)-3-chlorophenyl]acetic acid, 
         2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl)phenyl]propanoic acid, 
         2-[4-(2,5-dihydrothyen-2-yl carbonyl)phenyl]propanoic acid, 
         2-(5H-chromeno[2,3-b]pyridin-7-yl) propanoic acid, 
         4-(1,1′-diphenyl-4-yl)-4-oxobutanoic acid, 
         1,1′-diphenyl-4-yl acetic acid, 
         2-(6-methoxy-2-naphtyl) propanoic acid, 
         [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetic acid, 
         {5-methoxy-2-methyl-1-[(2E)-3-phenylprop-2-enoyl]-1H-indole-3-yl}acetic acid, 
         ({[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetyl}oxy)acetic acid, 
         (1,8-diethyl-1,3,4,9-tetrahydrofurane[3,4-b]indole-1-yl)acetic acid, 
         {(1E)-5-fluoro-2-methyl-1-[4-(methylsulphinyl)benzylidene]-1H-inden-3-yl}acetic acid, and 2-(6-chloro-9H-carbazol-2-yl) propanoic acid. 
       
     
     
         27 . The pharmaceutical composition according to  claim 26 , wherein the at least one taurine derivative compound is selected from the group consisting of:
 2-{2-[2-(2,6-dichlorophenylamino) phenyl]acetamide}ethanesulfonic acid,   2-{[(2,6-dichloro-3-methylphenyl)aminobenzoil]amide}ethanesulfonic acid,   2-{[3-(trifluoromethyl)phenyl]amino}nicotinoyl]amide}ethanesulfonic acid,   2-{[(2,3-dimethylphenyl)amino]benzoyl]amide}ethanesulfonic acid,   2-{[(2,4-dichlorophenoxy)phenyl]acetyl]amide}ethanesulfonic acid,   2-{[(3-chloro-2-methylphenyl)amino]benzoyl]amide}ethanesulfonic acid,   2-{[(1,2-diphenyl-hydrazino) carbonyl]hexanoyl]amide}ethanesulfonic acid,   4-{[(4-butyl-3,5-dioxo-1,2-diphenylpirazolidin-4-yl) methoxy]-4-oxobutanoyl]amide}ethanesulfonic acid,   {[(1,3,4-triphenyl-1H-pirazol-5-yl)acetyl]amide}ethanesulfonic acid,   {[[3-(4-chlorophenyl)-1-phenyl-1H-pirazol-4-yl]acetyl]amide}ethanesulfonic acid,   {[(1-benzyl-1H-indazol-3-yl)oxy]acetyl]amide}ethanesulfonic acid,   {[[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetyl]amide}ethanesulfonic acid,   {[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]acetyl]amide}ethanesulfonic acid,   3-{[(4,5-diphenyl-1,3-oxazol-2-yl)propanoyl]amide}ethanesulfonic acid,   {[[1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrol-3-yl]acetyl]amide}ethanesulfonic acid,   2-{[amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylyl]amide}ethanesulfonic acid,   [2-(2-hydroxybenzoyl)amide]ethanesulfonic acid,   {[[2-(aminocarbonyl)phenoxy]acetyl]amide}ethanesulfonic acid,   [(2,5-dihydroxybenzoyl)amide]ethanesulfonic acid,   {[2-(acetyloxy)benzoyl]amide}ethanesulfonic acid,   {[2-(sulphooxy)benzoyl]amide}ethanesulfonic acid,   2-{[(2-hydroxybenzoyl)oxy]benzoyl]amide}ethanesulfonic acid,   2-{[(2-phenylethyl)amino]benzoyl]amide}ethanesulfonic acid,   5-{[(2-phenyl-4,5-dihydro-3H-benzo[e]-1H-indole-2-(2-hydroxybenzoyl)amide]}ethanesulfonic acid,   [(2′,4′-difluoro-4-hydroxy-1,1′-diphenyl-3-carboxylyl)amide]ethanesulfonic acid,   2-{[2-(4-isobuthylphenyl) butanoyl]amide}ethanesulfonic acid,   [2-(4-isobuthylphenyl) propanoyl]amide ethanesulfonic acid,   {2-[4-(thien-2-yl-carbonyl)phenyl]propanoyl}amide ethanesulfonic acid,   {2-(3-phenoxyphenyl) propanoyl}amide ethanesulfonic acid,   [chloro(3-chloro-4-cyclo-hexylphenyl)acetyl]amide ethanesulfonic acid,   [4-(3-chloro-4-cyclo-hexyl phenyl)-4-oxobutanoyl]amide ethanesulfonic acid,   (6-chloro-5-cyclo-hexylindane-1-carboxyl) amide ethanesulfonic acid,   2-{4-[(2-methylprop-2-enil)amino]phenyl-propanoyl}amide ethanesulfonic acid,   [2-(5-benzoylthien-2-yl) propanoyl]amide ethanesulfonic acid,   (5-benzoyl-2,3-dihydro-1H-pyrolizine-1-carboxyl) amide ethanesulfonic acid,   {2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoyl}amide ethanesulfonic acid,   {2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoyl}amide ethanesulfonic acid,   [2-(3-benzoylphenyl) propanoyl]amide ethanesulfonic acid,   [2-(4-imidazo[1,2-a]pyridin-2-yl phenyl) propanoyl]amide ethanesulfonic acid,   {[1-methyl-5-(4-methylbenzoyl)-1H-pyrol-2-yl]acetyl}amide ethanesulfonic acid,   {[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrol-2-yl]acetyl}amide ethanesulfonic acid,   {2-[3-chloro-4-(2,5-dihydro-1H-pyrol-1-yl)phenyl]propanoyl}amide ethanesulfonic acid,   [(11-oxo-6,11-dihydroxibenzo[b,e]oxepin-2-yl)acetyl]amide ethanesulfonic acid,   [2-(2-fluoro-1,1′-diphenyl-4-yl) propanoyl]amide ethanesulfonic acid,   {[4-(allyloxy)-3-chlorophenyl]acetyl}amide ethanesulfonic acid,   {2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl)phenyl]propanoyl}amide ethanesulfonic acid,   {2-[4-(2,5-dihydrothien-2-yl carbonyl)phenyl]propanoyl}amide ethanesulfonic acid,   2-{[(5H-chromeno[2,3-b]pyridin-7-yl) propanoyl]amide}ethanesulfonic acid,   4-{[(1,1′-biphenyl-4-yl)-4-oxobutanoyl]amide}ethanesulfonic acid,   [(1,1′-biphenyl-4-yl acetyl)amide]ethanesulfonic acid, 2-{[2-(6-methoxy-2-naphthyl) propanoyl]amide}ethanesulfonic acid,   [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetyl]amide}ethanesulfonic acid,   {[(5-methoxy-2-methyl-1-[(2E)-3-phenylprop-2-enoyl]-1H-indole-3-yl)acetyl]amide}ethanesulfonic acid,   [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]acetyl}oxy)acetyl]amide}ethanesulfonic acid,   {[(1,8-diethyl-1,3,4,9-tetrahydrofuran[3,4-b]indole-1-yl)acetyl]amide}ethanesulfonic acid,   {[((1E)-5-fluoro-2-methyl-1-[4-(methylsulphonyl)benzylidene]-1H-inden-3-yl)acetyl]amide}ethanesulfonic acid, and   2-{[(6-chloro-9H-carbazol-2-yl) propanoyl]amide}ethanesulfonic acid.   
     
     
         28 . The pharmaceutical composition according to  claim 26 , wherein the at least one taurine derivative compound is selected from the group consisting of: 2-{2-[2-(2,6-dichlorophenylamino) phenyl]acetamide}ethanesulfonic acid; [2-(4-isobuthylphenyl) propanoyl]amide ethanesulfonic acid; 2-{[2-(6-methoxy-2-naphthyl) propanoyl]amide}ethanesulfonic acid; (5-benzoyl-2,3-dihydro-1H-pyrolizine-1-carboxyl) amide ethanesulfonic acid; 2-{[2-(4-isobutylphenyl) butanoyl]amino}ethanesulfonic acid; and [1-(4-chlorobenzoyl)-5-metoxy-2-methyl-1H-indole-3-yl]acetyl]amino}ethanesulfonic acid.